at Henry Ford Health System . “Through global collaboration, GBM AGILE is making it possible for some of the world’s foremost experts in glioblastoma research and treatment to collaborate and advance the pace at which scientific and clinical breakthroughs can be achieved.” After opening at Henry Ford Cancer Institute, the two new interventions –
VAL-083 from Kintara Therapeutics, Inc. and
paxalisib from Kazia Therapeutics Limited– will subsequently open at more than 35 trial sites across the United States, with additional global sites in Canada, Europe and China to follow.
VAL-083 is being evaluated in all three glioblastoma patient subtypes: newly-diagnosed methylated MGMT; newly-diagnosed unmethylated MGMT; and recurrent.
DBusiness Magazine
Henry Ford Health System First in World to Test Treatments for Brain Cancer
Detroit-based Henry Ford Cancer Institute has announced it is the first site in the world to activate two treatments for glioblastoma, the deadliest form of brain cancer, as part of a patient-centered adaptive platform trial called GBM AGILE.
Henry Ford Cancer Institute is the first on the planet to active two treatments for the deadliest form of brain cancer. // Photo courtesy of Henry Ford Health System
Detroit-based Henry Ford Cancer Institute has announced it is the first site in the world to activate two treatments for glioblastoma, the deadliest form of brain cancer, as part of a patient-centered adaptive platform trial called GBM AGILE.
E-Mail
IMAGE: Tom Mikkelsen, M.D., principal investigator for GBM AGILE at Henry Ford Cancer Institute, and medical director of the Precision Medicine Program and Clinical Trials Office at Henry Ford Health System.. view more
Credit: Henry Ford Health System
DETROIT (Feb. 3, 2021) - Henry Ford Cancer Institute is the first site in the world to activate two new treatments for glioblastoma (GBM), the deadliest form of brain cancer, as part of a patient-centered adaptive platform trial known as GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment). Led by Global Coalition for Adaptive Research (GCAR), GBM AGILE tests multiple therapies for patients with newly-diagnosed and recurrent GBM.
Health care inequities focus of Michigan State University, Henry Ford Health System partnership
Updated Jan 27, 2021;
Facebook Share
EAST LANSING, MI Michigan State University and Henry Ford Health System have formalized a 30-year partnership aimed to make Michigan a leader in providing access to health care for all residents.
Both institutions are committed to aligning efforts across departments and programs to achieve critical health care and educational goals, while addressing social issues that impact health outcomes for patients, according to a Henry Ford Health System news release.
Diversity, equity and inclusion are core components of the partnership, which includes fostering research, providing cancer care, interprofessional training, increasing diversity among the next generation of health care professionals and addressing the needs of traditionally underserved communities, according to the release.
The Henry Ford Cancer Institute Installs its Second ViewRay MRIdian® Linac
Second MRIdian System to be Installed at Henry Ford Health System s New Cancer Pavilion in Detroit
News provided by
Share this article
Share this article
CLEVELAND, Jan. 26, 2021 /PRNewswire/ ViewRay, Inc. (NASDAQ: VRAY) announced today that Henry Ford Cancer Institute has installed its second MRIdian Linac at its new cancer pavilion, Henry Ford Cancer Institute – Detroit, which began offering patient care on January 20, 2021.
Following FDA-clearance of the MRIdian Linac in February 2017, Henry Ford Cancer Institute became the first center in the world to install the next-generation system at one of its sites in Grosse Pointe Farms, Michigan. The MRIdian Linac was the first commercially available device to combine MRI-guidance with linear accelerator radiation delivery.